OXB Posts Strong Revenue Growth but Faces Integration Challenges — Oxford BioMedica plc (OXB)

Event summary

OXB reported a 33% revenue growth to £170.9 million in 2025, achieving full-year Operating EBITDA profitability.
The company acquired an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC for $4.5 million.
Contracted value of orders increased by 20% YoY to £224 million, reflecting strong commercial momentum.
Financial guidance for FY 2026 includes revenues between £220-240 million and Operating EBITDA margin of approximately 10%.
Cash at year-end was £96.9 million, up from £60.7 million in 2024.

The big picture

OXB's strong financial performance in 2025 underscores its strategic execution as a pure-play CDMO in the cell and gene therapy sector. The acquisition of the Durham, NC facility positions the company to capture market share in the growing viral vector manufacturing space. However, integrating this new asset efficiently will be key to sustaining its growth momentum amidst increasing competition and regulatory scrutiny.

What we're watching

Integration Challenges: The pace at which OXB can integrate and ramp up the Durham, NC facility will be critical to meeting its revenue and profitability targets.
Market Demand: Whether the strong demand for viral vector manufacturing services can sustain the company's growth trajectory in a competitive market.
Financial Discipline: How OXB balances its expansion plans with disciplined cost control to maintain profitability.